Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer.
Yukiko WadaKeiichi OkanoKiyotoshi SatoMasahiro SugimotoAyaka ShimomuraMina NagaoHiroyuki MatsukawaYasuhisa AndoHironobu SutoMinoru OshimaAkihiro KondoEisuke AsanoTakayoshi KishinoKensuke KumamotoHideki KobaraHideki KamadaTsutomu MasakiTomoyoshi SogaYasuyuki SuzukiPublished in: Japanese journal of clinical oncology (2022)
The present study identifies several important metabolic consequences and potential neoadjuvant chemoradiation therapy targets in pancreatic ductal adenocarcinoma. Choline metabolism is one of the key pathways involved in recurrence of the patients with pancreatic ductal adenocarcinoma who received neoadjuvant chemoradiation therapy.